Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INCENTA · Entity 5673 | Director | March 11, 2026 | March 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ENANTA PHARMACEUTICALS INC
Report date March 11, 2026 · Filed March 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.17 · Expires 2036-03-11 | Direct | 20,000 |
Reported balance
After 2026-03-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-11 · Grant · Acquired 20,000 · Balance 20,000 F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2026 Filed Mar 13, 2026 20:20 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $14.17 | $0.00 |
DisclosureSEC source: 0002064832-26-000143 · form4.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2036-03-11 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 11, 2026), with the final monthly installment vesting no later than the nearest trading day on the Nasdaq Global Select Market preceding the 2027 annual meeting of stockholders. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 21:44 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0001062993-25-005507 · form4.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2035-03-13 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 13, 2025), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2026 annual meeting of stockholders. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 22:30 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 15,700 | $0.00 Strike: $15.66 | $0.00 |
DisclosureSEC source: 0001062993-24-006052 · form4.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2034-03-06 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders. Read SEC document |
| December 13, 2023 Filed Dec 16, 2023 01:08 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | SaleCommon Stock | 15,295 | $9.12 | $139,490.40 |
DisclosureSEC source: 0001062993-23-022695 · form4.xml · nonDerivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,800 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $8.80 to $9.56, inclusive. The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:46 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionStock Option (right to buy) · Derivative | 5,800 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001062993-23-007225 · form4.xml · derivative · entry 2 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,800 shares Expires 2023-03-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| March 16, 2023 Filed Mar 17, 2023 22:46 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | Exercise / conversionCommon Stock | 5,800 | $14.00 | $81,200.00 |
DisclosureSEC source: 0001062993-23-007225 · form4.xml · nonDerivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 22:21 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 10,800 | $0.00 Strike: $47.72 | $0.00 |
DisclosureSEC source: 0001062993-23-006097 · form4.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,800 Underlying: Common Stock · 10,800 shares Expires 2033-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2023), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2024 annual meeting of stockholders. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 23:52 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $68.22 | $0.00 |
DisclosureSEC source: 0001062993-22-007013 · form4.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2032-03-03 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 3, 2022), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2023 annual meeting of stockholders. Read SEC document |
| March 02, 2021 Filed Mar 4, 2021 23:45 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $49.92 | $0.00 |
DisclosureSEC source: 0001177648-21-000019 · edgar.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-02 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 2, 2021), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2022 annual meeting of stockholders. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:24 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $51.04 | $0.00 |
DisclosureSEC source: 0001177648-20-000020 · edgar.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-02-26 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 26, 2020), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2021 annual meeting of stockholders. Read SEC document |
| February 28, 2019 Filed Mar 2, 2019 01:08 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $102.54 | $0.00 |
DisclosureSEC source: 0001177648-19-000024 · edgar.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2029-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2019), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2020 annual meeting of stockholders. Read SEC document |
| February 28, 2018 Filed Mar 6, 2018 00:36 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $78.62 | $0.00 |
DisclosureSEC source: 0001177648-18-000019 · edgar.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-02-28 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 28, 2018), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2019 annual meeting of stockholders. Read SEC document |
| February 16, 2017 Filed Feb 22, 2017 00:42 UTC | ENANTA PHARMACEUTICALS INC ENTA · Entity 5673 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $29.02 | $0.00 |
DisclosureSEC source: 0001177648-17-000018 · edgar.xml · derivative · entry 1 Vance Terry · CIK 0001572282 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-02-16 F1 · derivative.exercise_date: Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (February 16, 2017), with the final monthly installment vesting at the 2018 annual meeting of stockholders. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.